Johnson & Johnson (JNJ) Company Profile & Statistics

Johnson & Johnson
JNJ
(NYSE)
N/A
153.41
+0.37 (+0.24%)
in:usd•As of: May 17, 2024 15:59 UTC -4
Pre Market:153.68-0.97 (-0.63%)
Open
153.21
High
153.50
Low
152.55

About Johnson & Johnson

CEO

J. Duato

Headquarters

one johnson & johnson plz

new brunswick, nj 08933, united states

Auditor

PricewaterhouseCoopers LLP

Employees

131,900

Share Holders

124,211

Website

http://www.jnj.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

Johnson & Johnson Statistics

Valuation Measures

Market Capitalization ²	369.21B
Enterprise Value	377.37B
Enterprise Value/EBITDA (ttm)	12.74
Price to Earnings Ratio (ttm)	14.78
Price to Book (mrq)	5.32
Price to Sales (ttm)	4.15
Price to Cash (ytd)	11.32

Profitability

Gross Margin (ttm)	69.35%
Operating Margin (ttm)	29.31%
Profit Margin (ttm)	45.14%
Return on Equity (ttm)	36.70%
Return on Invested Capital (ttm)	17.13%
Return on Assets (ttm)	15.07%

Income Statement

Revenue (ttm)	85.65B
Revenue Per Share (ttm)	35.59
Gross Profit (ttm)	59.27B
EBITDA (ttm)³	29.63B
Net Income Avi to Common (ttm)	38.48B
Diluted EPS (ttm)	16.04

Share Statistics

Beta (5Y Monthly)	0.55
52-Week Change	0.86%
S&P500 52-Week Change	26.49%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	2.41B
Dividend Yield	3.08%
Float ⁴	2.40B
% Held by Insiders	0.16%
% Held by Institutions	69.55%

Balance Sheet

Total Cash (mrq)	26.22B
Total Cash Per Share (mrq)	10.89
Total Debt (mrq)	33.63B
Total Debt/Equity (mrq)	48.03%
Current Ratio (mrq)	1.17%
Quick Ratio (mrq)	0.94%
Book Value Per Share (mrq)	29.09

Cash Flow

Operating Cash Flow Per Share (ytd)	1.50
Free Cash Flow (ytd)	3.06B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Johnson & Johnson

Trade With A Regulated Broker